# A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

> **NCT00437424** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 24 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Brivanib

## Key facts

- **NCT ID:** NCT00437424
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437424, "A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00437424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*